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86David C. Yang, MS and Ching-Hsien Chen, PhDSummary: Renal cell carcinoma (RCC) is increasing in incidence and one third of newly diagnosed cases already
are metastatic. The metastatic spread of solid tumors renders RCC incurable by surgical resection and conse-
quently more difficult to treat. New molecular-targeted therapies have played a pivotal role in RCC treatment. Unfor-
tunately, tumors frequently develop resistance to these targeted therapies by activating bypass pathways in which
alternative signaling or biochemical pathways are activated in response to targeted inhibition of a signaling pathway,
allowing cancer cells to continue to survive. Although the advent of immunotherapy with checkpoint inhibitors has
led to significant changes in the treatment landscape for advanced RCC, many issues remain to be resolved. For
these reasons, there is an urgent need to develop novel therapies and new treatment paradigms for patients with
RCC. Much research has been performed thus far in identifying novel targets and treatment strategies in RCC and
many of these currently are under investigation and/or in clinical trials. In this article, we discuss therapeutic options
in the management of RCC with a focus on the new therapeutic approaches currently investigated in research and
for use in the clinic. We divide these potential novel therapies into five groups: nonbiologics, small-molecule drugs,
biologics, immunomodulatory therapies, and peptide drugs. We also present some therapeutics and treatment
paradigms.
Semin Nephrol 40:86−97  2019 The Author(s). Published by Elsevier Inc. This is an open access article under the
CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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enal cell carcinoma (RCC) is a frequently lethal
urological disease and is currently the ninth most
common cancer in men and the 14th most com-
mon in women worldwide. The disease accounts for
roughly 403,000 new cases (2.2% of all diagnoses) and
roughly 175,000 deaths (1.8% of all cancer-related
deaths) yearly.1 In the United States, RCC accounts for
roughly 74,000 (4.2%) new cases and 15,000 (2.4%)
deaths yearly.2 RCC primarily afflicts patients in the fifth
or sixth decades of life,3 and primarily affects men at
roughly a 2:1 ratio.4 Approximately 65% of patients
with RCC who present to the clinic have localized
tumors that typically are treated and potentially cured
via total or partial nephrectomy. The remaining 35% of
patients present with metastatic RCC, which often is
incurable by surgical removal, necessitating the use of
systemic treatments. RCC has a wide range of subtypes,
with the most common being clear cell carcinoma, whichpartment of Internal Medicine, University
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mnephrol.2019.12.010accounts for approximately 75% of all RCCs. Other sub-
types such as papillary (10%), chromophobe (5%), and
other less common subtypes account for the remainder
of cases.5
Risk factors for RCC include multiple genetic and
nongenetic factors. Nongenetic factors, such as obesity,
hypertension, smoking, chronic use of pain medications,
and exposure to certain chemicals (eg, trichloroethy-
lene), have been implicated in the pathogenesis of
RCC.6 Genetic risk factors include BRCA1-associated
protein-1, folliculin, fumarate hydratase, hepatocyte
growth factor receptor, phosphatase and tensin homolog,
succinate dehydrogenase complex iron sulfur subunit B,
succinate dehydrogenase complex subunit C, succinate
dehydrogenase complex subunit D, tuberous sclerosis
1 complex subunit 1, tuberous sclerosis 1 complex
subunit 2, and von Hippel-Lindau tumor-suppressor
(VHL) genes.4 Of these factors, the most well-defined,
researched, and frequently observed is VHL. This tumor-
suppressor gene encodes the VHL protein, which is an
E3-ubiquitin ligase that plays a role in promoting the
degradation of hypoxia-inducible factor 1a (HIF-1a)
under normal conditions.7
In RCC, the VHL gene often is silenced or lost, result-
ing in unrestricted activation of HIF-1a target genes,
which leads to the up-regulation of an array of proangio-
genic genes including vascular endothelial growth factor
(VEGF), dysregulation of cellular metabolism, and apopto-
sis, which drive the highly vascularized pathology
observed.7,8 The phosphatidyl-inositol-3-kinase−protein
kinase B (AKT)-mammalian target of rapamycin (mTOR)
pathway is thought to be a driver of RCC, with frequent
mutations in this pathway observed in tumors.9 Much ofSeminars in Nephrology, Vol 40, No 1, January 2020, pp 86−97
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understanding of the molecular basis of RCC; many first-
and second-line treatments concentrating on various targets
such as VEGF and mTOR have been approved and in
clinical use within the past decade, with many more thera-
pies currently undergoing clinical trials.10CURRENT MANAGEMENT OF RCC
When patients with RCC present to the clinic, the RCC
most often is treated via surgical resection if the tumor is
localized. This is accomplished through partial or total
(radical) nephrectomies in which the tumor tissue is
removed surgically. This may result in a complete cure,
but 20% to 40% of RCC cases still return with resurgent
tumors after the initial removal.11 Surgical removal also
may be complicated or rendered impossible by the prox-
imity to the vasculature, the ureter, and other areas that
are intractable to surgical removal. In addition, total
removal or removal of a large portion of the kidney mass
may give rise to complications such as chronic kidney
disease and loss of kidney function. For patients who
present with advanced disease in which the tumor
already has spread, systemic treatments may be the only
option.12,13 Historically, systemic treatments have con-
sisted of interferon (IFN) and interleukin (IL)2, which
provided some durable responses in a small percentage
of patients (7%-8%) but had significant drawbacks in
toxicity and provided only a meager median survival of
12 months. These limitations, along with an increasing
breadth of knowledge on the molecular basis and biology
of renal tumors, have led to rapid advances in the field in
the past decade and more.4
With the introduction of sorafenib in 2005, the treat-
ment landscape for patients with RCC was revolutionized.
Since then, many more therapies have been investigated
and approved for clinical use. Today, there are 11 Food
and Drug Administration−approved therapies for first-line
and second-line treatments targeting a wide array of tar-
gets including VEGF (bevacizumab, lenvatinib, cabozanti-
nib, pazopanib, axitinib, sorafenib, and sunitinib), mTOR
(everolimus and temsirolimus), immunomodulatory tar-
gets such as programmed cell death protein 1 (PD-1;
nivolumab and pembrolizumab) and programmed death-
ligand 1 (PD-L1; avelumab and atezolizumab), and other
signaling molecules (lenvatinib, cabozantinib, pazopanib,
axitinib, sorafenib, and sunitinib).13-15 Currently, there is
an effort to uncover the factors underlying treatment
response to tailor therapies to individual patients. Work
currently is underway and we likely will see the fruits of
this labor in the coming years.THERAPEUTIC CHALLENGES IN RCC
Treatment of advanced RCC often is complicated by a
plethora of factors. Of note, there may be significantintertumor and intratumor heterogeneity,9 potentially
explaining why patients may have a good initial response
to frontline therapies but also may have relapsing tumors
that are resistant. It has been shown that within the
tumor, there is a wide array of clones present with differ-
ent mutations, suggesting clonal evolution giving rise to
heterogeneous tumors that are difficult to target. In addi-
tion, patient responses to therapies are not equal, some
patients may benefit greatly from a certain type of ther-
apy whereas another patient may have a minimal
response. The tumor itself also may adapt to therapies
and become resistant to therapeutics through modulation
of alternative biochemical or signaling pathways, recruit-
ment of supporting cells, sequestration or removal of
drugs, and also increasing invasion through promoting
mesenchymal transition.16 Figure 1 summarizes multiple
strategies that exist to target RCC tumors through differ-
ent cell types. In addition to an overview of the current
practices (Fig. 2) and challenges with these therapies,
this article presents potential novel therapeutic
approaches and future directions in the management of
this disease (Fig. 3).NEW TREATMENT OPTIONS AND STRATEGIES
FOR RCC
Nonbiologics
RCC tumors typically are thought to be radiation-resis-
tant tumors, typically used in a palliative setting to
address distant metastases such as in the brain and bone.
However, as suggested by De Felice and Tombolini17 in
their review of radiation therapy in RCC, radiation ther-
apy still may be a promising technique in the nonpallia-
tive setting. Of particular note, the use of stereotactic
techniques in stereotactic body radiation therapy, which
allows for precise control over the treatment area, has
provided a way for targeted dosages of radiation to
ablate primary tumors and metastases with minimal
damage to surrounding tissue. In addition, the use of
hypofractionated radiation, that is, a higher dose of radi-
ation (>3 Gy/fraction), has been shown to be effective.
In lower conventional dosages, tumor cell death is medi-
ated through the classic p53 pathway. This presents a
problem because most RCC tumors have VHL defi-
ciency, leading to up-regulation of proangiogenic factors
such as VEGF and fibroblast-derived growth factor,
which promotes cell survival. In higher doses of radia-
tion (>8 Gy/fraction), the sphingomyelin pathway is
activated in cells, leading to ceramide-mediated cell
death and collapse of the vasculature. This method also
has shown low toxicity and good control of local tumors
and may be a promising strategy to target primary
tumors or manage metastases in patients.18
The use of stereotactic body radiation therapy is a
current area of investigation with multiple trials being
Figure 2. Current targeted therapies for RCC. In the clinic, multiple targeted therapeutics are used to target (A) angio-
genesis, tumor cell growth, and (B) the immune response. Abbreviations: AXL, AXL receptor tyrosine kinase; CTLA-4,
cytotoxic T-lymphocyte-associated protein 4; FGFR, fibroblast growth factor receptor; FLT3, fms like tyrosine kinase 3;
KIT, mast/stem cell growth factor receptor; MET, hepatocyte growth factor receptor; PDGFR, platelet-derived growth
factor receptor; RAF, rapidly accelerated fibrosarcoma kinase; RET, rearranged during trasnfection proto-oncogene;
VEGFR, vascular endothelial growth factor receptor.
Figure 1. Approaches to target RCC. Multiple approaches exist to target RCC tumors through different cell types.
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Figure 3. Novel targets for therapies in RCC. A range of factors in the immune cells, the tumor cells themselves, as well
as the endothelial cells present as promising targets for therapeutic targeting. Abbreviations: AKT1, RAC-alpha serine/
threonine-protein kinase; ALK-1, activin receptor-like kinase 1; BTK, bruton tyrosine kinase; GITR, glucocorticoid-
induced TNFR-related protein; TIE2, angiopoietin-1 receptor; VISTA, V-domain Ig suppressor of T-cell activation.
Novel therapeutics for kidney cancer 89run in the United States (NCT03065179, NCT02542202,
NCT01896271, NCT03575611, NCT02141919,
NCT01890590, NCT02781506, and NCT02782715) as a
single therapy or in combination with other therapies
(Table 1). Of interest, Cyberknife, a robotic radiation
system developed by Accuray (Sunnyvale, CA), cur-
rently is undergoing clinical trials to assess its efficacy in
a wide array of malignancies. This system provides the
capability to accurately deliver targeted doses of radia-
tion through the use of a robotic guidance system with a
complementary image guidance system. The system has
been tested and has shown local control of the tumor and
low toxicity,19 suggesting that this method may be a via-
ble option for patients who may be precluded from surgi-
cal resection or systemic treatment.
Surgical reduction of renal tumors offers a potentially
curative route for RCC. Surgical removal of renal tumor
masses is standard procedure, and recent advances in
minimally invasive procedures and nephron-sparing sur-
gery and partial nephrectomies have shown a consider-
ably favorable disease-free survival rate greater than
97.5%. These types of surgeries also do much to preserve
renal function while achieving similar tumor control
compared with radical nephrectomy. Other surgicalpractices such as cytoreductive nephrectomy and meta-
stasectomy have shown good outcomes for patients and
may be complementary with targeted therapies.20,21 In
addition, debulking of the tumor before surgery has
shown some promise with rendering previously unresect-
able tumors to being amenable to nephron-sparing sur-
gery and partial nephrectomy. Currently, the utilization
of immunotherapies in the preoperative setting is an
active area of investigation with multiple clinical trials
underway, and it remains to be seen whether or not these
therapies could improve surgical treatment in RCC.22Small MoleculesImmune Response
Targeted therapies with small-molecule drugs remain a
mainstay of therapy for advanced RCC and relapsed
RCC. Before 1998, much of cancer therapy relied on
chemotherapy, which had a wide array of adverse effects
owing to the untargeted nature of chemotherapeutic
drugs. With the advent of imatinib in 1998, small-mole-
cule inhibitors have transformed the treatment landscape
Table 1. Novel Therapeutics for RCC
Drug/Treatment Drug Type Target Mechanism Active Clinical Trials
Hypofractionated
radiation/SBRT
Radiation Tumor cells Ceramide-mediated cell death, collapse of vasculature NCT03065179, NCT02542202,
NCT01896271, NCT03575611,
NCT02141919, NCT01890590,
NCT02781506, NCT02782715
MK-1454 Small molecule STING agonist Activation of cross-presentation by APCs NCT03010176
MK-46212 Small molecule RIG-1 agonist Stimulation of IFN response, activation of immune cells NCT03739138
Dalantercept Small molecule ALK-1 inhibitor Blocking ALK-1−mediated angiogenesis NCT01727336
Ibrutinib Small molecule BTK, ITK inhibitor Shift of Th1 and Th2 balance, promoting antitumor
response
NCT02599324, NCT02899078
Abemaciclib Small molecule CDK4/6 inhibitor Disruption of CDK4/6 and G1 to S cell-cycle transition NCT03905889
Vorinostat Small molecule HDAC inhibitor Reduction of proliferation and activation of apoptosis NCT02619253
Abexinostat Small molecule HDAC inhibitor Reduction of proliferation and activation of apoptosis NCT03592472
CT053PTSA Small molecule VEGFR2, c-MET,
AXL, FLT3, and
Mer inhibitor
Inhibition of angiogenesis and tumor progression NCT03876925
CB-839 Small molecule Glutaminase
inhibitor
Reducing cell proliferation and survival NCT03163667, NCT03428217,
NCT02771626, NCT03875313,
NCT02071862
Epacadostat Small molecule IDO1 inhibitor Promotes effector T-cell activity by down-regulating immu-
nosuppressive environment
NCT03260894, NCT02178722,
NCT03277352
AS1411 DNA aptamer DNA synthesis Binds to nucleolin and prevents DNA synthesis N/A
RX-0201 Antisense oligonucelotide AKT1 antisense Targets AKT1 mRNA, preventing translation NCT02089334 (terminated)
AGS-16C3F Targeted toxin Tumor cells Internalized by tumor cells and exerts cytotoxicity NCT02639182
Pexastimogene
devacirepvec
Oncolytic vaccinia virus Tumor cells Replicates in and lyses tumor cells, promotes immune
response through expressing GM-CSF and
b-galactosidase
NCT03294083, NCT02977156
Anti-VISTA Immunomodulatory T cells Blockade improves T-cell activity N/A
Anti-TIM-3 Immunomodulatory T cells Inhibition increases T-cell proliferation and cytokine
production
NCT02817633, NCT03708328,
NCT02608268
Anti−LAG-3 Immunomodulatory T cells Inhibition results in immune activation NCT03538028, NCT03849469,
NCT02460224
CD40/CD154 agonist Immunomodulatory APCs Binding leads to B-cell and T-cell activation NCT03502330, NCT03538028
GITR agonist Immunomodulatory T cells Activation of T cells NCT02697591, NCT03277352,
NCT03126110
CD137 agonist Immunomodulatory T cells Promotes T-cell proliferation and activation NCT03809624, NCT02315066
CD25 Immunomodulatory Treg cells Depletion of immunosuppressive Treg cells N/A
AGS-003 DC therapy DCs Primes immune response to tumor N/A
HIF-1a278-287 Peptide vaccine APCs, T cells Priming immune system against HIF-1a N/A
Neovax Peptide vaccine APCs, T cells Priming immune system against personalized tumor
antigens
NCT02950766
CAR-T cells Adoptive cell transfer T cells Engineered T cells targeting tumor cells NCT02830724, NCT03399448
AMG-386 Peptide Endothelial cells Prevents Ang1/2 binding to TIE2, preventing angiogenesis NCT01664182, NCT03239145
HBS1 Peptide Tumor cells Prevents transcription of HIF-1a target genes via binding
to p300 and CBP
N/A
Multiple investigational drugs currently are being evaluated for clinical use in multiple clinical trials. The mechanism of action and active clinical trials to the best of our knowledge are listed.
Abbreviations: AKT1, RAC-alpha serine/threonine-protein kinase; ALK-1, activin receptor-like kinase 1; AXL, AXL receptor tyrosine kinase; BTK, bruton tyrosine kinase; CBP, cAMP
response element-binding protein-binding protein; CAR-T, chimeric-antigen receptor T; c-MET, hepatocyte growth factor receptor; FLT3, fms like tyrosine kinase 3; GITR, glucocorticoid-
induced tumor necrosis factor−receptor family-related protein; GM-CSF, granulocyte macrophage colony-stimulating factor; ITK, interleukin-2-inducible T-cell kinase; Mer, Proto-oncogene
tyrosine-protein kinase MER; mRNA, messenger RNA; SBRT, stereotactic body radiation therapy; Th1, T helper type 1; Th2, T helper type 2; TIE2, angiopoietin-1 receptor; Treg, T regula-
tory; VEGFR2, vascular endothelial growth factor receptor 2; VISTA, V-domain Ig suppressor of T-cell activation.
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Novel therapeutics for kidney cancer 91in cancer therapy. Showing an impressive 95% complete
response rate in chronic myeloid leukemia, this landmark
study propelled the world into the era of targeted ther-
apy.23 Since 2005, much of the current standard thera-
pies for RCC and metastatic RCC have included small-
molecule inhibitors of various receptors and other signal-
ing molecules at play in the disease. The majority of the
focus has been placed on the VEGF-receptor and mTOR
pathways, but targeting of other pathways with a wide
array of different small-molecule inhibitors is an active
area of investigation. Herein, we provide an overview of
several small molecules on the horizon of the therapy
landscape in RCC.
The stimulator of interferon genes (STING) pathway
is part of the innate immune system responsible for sens-
ing DNA from pathogens and mounting an immune
response. Upon activation, the pathway induces the pro-
duction of type 1 IFNs, which in turn activates cross-
presentation of tumor antigens by antigen-presenting
cells (APCs) and promotes a proinflammatory tumor
environment. The antigen presentation induced tumor
infiltration of CD4+ and CD8+ T cells and activated
these cell types to kill tumor cells.24,25 Given this activ-
ity, the STING agonist MK-1454 was developed to acti-
vate this pathway through binding to STING. There is
currently one phase I clinical trial underway set to com-
plete in 2021 (NCT03010176).
Likewise, the RIG-1 agonist MK-46212 exerts its
effects through a similar mechanism. Binding to RIG-1,
the agonist stimulates IFN response, in turn activating
immune cells such as CD8+ T cells and natural killer
(NK) cells to destroy the tumor cells.25 There is currently
one active trial underway for this therapeutic agent for
solid tumors (NCT03739138).
Activin receptor-like kinase 1 (ALK-1) plays a well-
studied role in angiogenesis.26 Given the role of this kinase
in modulating angiogenesis, inhibition of the receptor tyro-
sine kinase has been considered as a therapeutic strategy in
RCC owing to the vascular nature of the disease. Dalanter-
cept, an ALK-1 inhibitor, had shown promise in a phase I
clinical trial with 13 patients achieving stable disease and
1 patient with a partial response.27 Furthermore, the com-
bination of dalantercept with multikinase inhibitor suniti-
nib had promising antitumor effects in vivo.28 However, in
a phase II clinical trial (NCT01727336), dalantercept in
combination with multikinase inhibitor axitinib showed no
improvement in treatment outcome despite being well tol-
erated. It remains to be seen whether dalantercept could be
combined with immunotherapy drugs such as pembrolizu-
mab or nivolumab given dalantercept’s proinflammatory
effects through modulation of IFNs.
Ibrutinib is a bruton’s tyrosine kinase inhibitor that
also has activity on IL2-inducible T-cell kinase. Signal-
ing through these receptors modulates B-cell and T-cell
activation. Down-regulation of these signaling pathways
has been suggested to shift the T helper type 1/T helpertype 2 T-cell ratio and to enhance antitumor immune
responses.29,30 For this reason, ibrutinib has been consid-
ered for use in RCC and a study has found some antitu-
mor effects in two patients treated when used in
combination with nivolumab.31 Currently, there are two
active clinical trials examining the use of ibrutinib in
RCC (NCT02599324 and NCT02899078).Cell Nucleus and Signaling
Cyclin-dependent kinases (CDKs) are important regula-
tors of the cell cycle through mediating progression
through phases in the cell cycle. Of note, CDK4 and
CDK6 play a role in phosphorylation of the retinoblas-
toma protein, transitioning the cell from the G1 phase to
the S phase, allowing cells to proliferate. The retinoblas-
toma protein has been shown to be expressed in 95% of
RCCs and may be a viable target to stop tumor prolifera-
tion. Abemaciclib is a potent CDK4/6 inhibitor that pre-
vents the phosphorylation of the retinoblastoma protein
by disrupting the activity of CDK4/6.32 It has shown effi-
cacy in a xenograft mouse model of RCC with a signifi-
cant reduction in tumor volume and in vitro cell models
of RCC with treatment promoting cell apoptosis. Based
on the promising preclinical results, abemaciclib cur-
rently is being evaluated for clinical use in combination
with sunitinib (NCT03905889).
Histone deacetylases (HDACs) have been shown to be
overexpressed in RCC tissues and it has been observed that
overall acetylation of proteins is lower in RCC.33 Inhibition
of HDAC activity can result in activation of apoptosis and
reduction of proliferation. These findings indicate that
HDACs may be a potential target. There are a few exam-
ples of HDAC inhibitors being investigated for use in RCC
with vorinostat and abexinostat. In clinical trials, vorinostat
with bevacizumab showed clinical benefit with 6 patients
having a complete or partial response.34 Abexinostat,
which functions similarly through inhibition of HDACs,
has been shown to provide durable responses in patients,
with six patients in the trial experiencing a partial response
lasting more than 2 years. In addition, 70% of the patients
in the trial who had prior disease progression on pazopanib
showed a reduction in tumor size during the trial.35 Vorino-
stat currently is being evaluated in combination with pem-
brolizumab in advanced RCC and urothelial cancers. The
phase III abexinostat trial in RCC still currently is under-
way and is expected to finish in 2022 (NCT03592472).
CT053PTSA is an inhibitor of VEGF-receptor 2,
hepatocyte growth factor receptor, AXL receptor tyro-
sine kinase, fms like tyrosine kinase 3, and proto-onco-
gene tyrosine-protein kinase MER. These signaling
molecules have been implicated to play roles in tumor
pathogenesis and angiogenesis. A study by Xi et al36
found CT053PTSA to be effective in inhibiting angio-
genesis and this inhibitor has shown good activity in a
wide range of tumor xenograft models. Currently, it is in
92 D.C. Yang and C.-H. Chena phase I trial in China and is expected to wrap up in
2020 (NCT03876925).Metabolic Pathways
Glutaminase is a metabolic enzyme that regulates gluta-
mine metabolism in the cell. In RCC, glutamine utiliza-
tion is increased in RCC and tumor cells become
addicted to glutamine.37,38 Exploiting this dependency,
glutaminase inhibitors could prove capable of shutting
down cellular proliferation and survival. CB-839 is a
glutaminase inhibitor that has been used in combination
with cabozantinib and has shown some promising results
in clinical trials, with a partial response or stable disease
achieved in most patients enrolled.39 There are five clini-
cal trials currently in progress evaluating its efficacy
in combination with various tyrosine kinase inhibitors or
immunotherapy agents (NCT03163667, NCT03428217,
NCT02771626, NCT03875313, and NCT02071862).
Indoleamine 2,3-dioxygenase 1 (IDO1) is an intracellu-
lar enzyme that catalyzes the conversion of tryptophan to
kynurenine. IDO1-mediated depletion of tryptophan and
production of other metabolites has been linked to an
immunosuppressive tumor environment in which effector
T-cell activity is reduced and immunosuppressive cell
activity is increased. A study by Trott et al40 indicated that
the failure of IFNa therapy likely was owing to the immu-
nosuppressive environment generated by increased levels
of IDO1. Epacadostat is an inhibitor of IDO1 that pro-
motes effector T-cell activity and down-regulates immuno-
suppressive cell types via inhibiting the degradation of
tryptophan by IDO1. Prior studies have shown that epaca-
dostat is well tolerated in patients and had promising clini-
cal activity. There currently are three clinical trials
(NCT03260894, NCT02178722, and NCT03277352) in
progress evaluating the efficacy of epacadostat in RCC
and a wide array of other neoplastic malignancies. Nota-
bly, in the trial using epacadostat in combination with
pembrolizumab, the study achieved objective response in
19% of the patients enrolled.41 Given the role of IDO1 in
modulating the immune response in the tumor environ-
ment and the results observed in this trial, we may see
more strategies combining immunotherapy with modula-
tors of the tumor immune environment.Biologics
Despite the successes of targeted therapies with small-mol-
ecule inhibitors, several challenges remain in the treatment
of RCC with targeted inhibitors. One of the most pressing
issues is the development of resistance to targeted thera-
peutics after an initial response. Kinase inhibition exerts a
strong selective pressure for development of resistance to
the inhibitor treatment and many acquired resistance
mechanisms can involve activation of alternative pathways
and mutations on the kinases targeted by therapeutics. Inaddition, targeting angiogenesis may promote increased
tumor invasiveness because cells may undergo epithelial-
mesenchymal transition to escape the hypoxic environ-
ment of the tumor resulting from decreased vasculariza-
tion.42,43 In lieu of targeting the protein of interest,
targeting the DNA and RNA may provide a promising
alternative route. Various microRNAs, long noncoding
RNAs (lncRNAs), various other noncoding RNAs, and
DNA synthesis are dysregulated in RCC.44,45 For
example, the lncRNA metastasis Associated Lung Adeno-
carcinoma Transcript 1 is associated with proliferation and
migration in RCC and targeting this lncRNA with short
hairpin RNA reduced these activities.46 A more compre-
hensive exploration of microRNAs and lncRNA in cancer
can be found in recent cancer studies.44,45,47 A wide range
of options exist to target these biomolecules. These include
the use of antisense oligonucleotides, which are modified
DNA that bind to targeted RNA; ribozymes, which are
enzymes that cleave RNA; small interfering RNA, which
are small RNAs that can target complementary RNAs; and
RNA sponges, which sequester RNAs, preventing them
from exerting their effects.44 In addition, nucleotide thera-
peutics also may have the potential to target protein
through shape-specific recognition.48 A few of these thera-
peutics are being evaluated for use in RCC.
AS1411 is a DNA aptamer that targets the nucleolin
protein, which is overexpressed in RCC. Binding of this
aptamer to nucleolin on the cell surface leads to the inter-
nalization of this complex and inhibits DNA synthesis in
the cells. In clinical testing, AS1411 showed limited effi-
cacy but had a few significant and durable responses in
select patients (one patient experienced an 84% decrease in
tumor dimensions).48 These findings suggest that further
studies are warranted to determine the patient population
that would benefit from this therapy. Up-regulated phos-
phatidyl-inositol-3-kinase/AKT activity frequently occurs
in a wide range of cancers. RX-0201 is an AKT-1 antisense
oligonucleotide that targets AKT-1 messenger RNA, pre-
venting the translation of the messenger RNA transcript. In
clinical trials, it has shown promising results with tumor
burden reduction and stable disease observed in some
patients.49,50 RX-0201 was being evaluated in combination
with mTOR inhibitor everolimus (NCT02089334); how-
ever, the study was terminated for unclear reasons.
Given that there are a plethora of RNAs at play in
RCC, with many having roles in modulating aspects of
tumor cell proliferation, invasion, and progression, we
may see more and more of these technologies transition
from preclinical studies into clinical practice, and per-
haps eventual clinical use.51-55Immunotoxins
Another potential avenue of treatment is the use of drugs
conjugated to antibodies or ligands to selectively target
cells with toxins.56,57 Much work already has been
Novel therapeutics for kidney cancer 93performed in this area, with many peptides and antibody
fragments being developed that can home to cancer cells
and are conjugated to a wide range of cytotoxic agents.56
One example of an antibody drug conjugate is AGS-
16C3F, which is currently in phase II clinical trial
(NCT02639182). AGS-16C3F comprises an antibody tar-
geting ectonucleotide pyrophosphatase/phosphodiesterase
3, which is overexpressed in RCC cells. Conjugated to
monomethyl auristatin F, AGS-16C3F has been shown to
be internalized by tumor cells and exert cytotoxic effects.
During the phase I trial for the drug, a portion of the
patients experienced partial response or stable disease
beyond 100 weeks and 37 weeks, respectively, indicating
that the therapy may benefit a subset of patients.58
Targeted therapy with oncolytic viruses is also a
promising direction. Pexastimogene devacirepvec is a
modified vaccinia virus that is able to selectively target
tumor cells via a thymidine kinase gene inactivation.
This inactivation renders the virus dependent on the
heightened thymidine kinase activity in tumor cells,
which can support viral replication. Furthermore, the
engineered virus expresses granulocyte macrophage col-
ony-stimulating factor and b-galactosidase transgenes,
which promote an immune response to the tumor.59 In a
phase II trial, pexastimogene devacirepvec showed dis-
ease control in 76% of the patients enrolled in the study
and also a complete response in one patient.60 Currently,
this virus is being evaluated in combination with other
therapeutics in two trials for solid tumors and RCC
(NCT03294083 and NCT02977156).Immunomodulatory
Modulation of the immune response is a critical part of a
complex system, controlling the immune response to
tumors and infections while protecting normal tissue
from damage. A wide range of cell types are at play in
this complex weave of interactions: T cells, B cells, NK
cells, macrophages, the subtypes of each cell, the tumor
stroma, and the tumor cells themselves are some of the
cell types at play in modulating the immune environment
within the tumor. Much focus has been placed on the
effector T cell in recent years with the focus of many
current drugs targeting cytotoxic T-cell inhibitory mole-
cules such as cytotoxic T-lymphocyte−associated pro-
tein 4, PD-1, and PD-L1. The intensive studies of these
molecules have resulted in many therapeutics in use in
the clinic today for RCC including pembrolizumab,
nivolumab, atezolizumab, and avelumab. Although these
targets have provided clinical benefit to many patients,
some patients do not respond to these therapies, under-
scoring the need to investigate other targets. Herein, we
provide some of the targets that may hold promise for
use in a therapeutic setting.
There is a vast array of other inhibitory or stimulatory
molecules at play in modulating the immune responsethat currently are being investigated. T-cell immuno-
globulin-3 (TIM-3) is a negative regulator of T cells and
is expressed on NK and macrophage cells and is found
on exhausted T cells in the tumor. Furthermore, it can
promote the expansion of immunosuppressive myeloid-
derived suppressor cells.61 Targeting of TIM-3 has been
shown to increase T-cell proliferation and increase cyto-
kine production, leading to a more robust immune
response. Currently, there are three clinical trials evalu-
ating TIM-3 targeting in RCC (NCT02817633,
NCT03708328, and NCT02608268).
V-domain Ig suppressor of T-cell activation is a stim-
ulator of antigen-presenting cells and a negative regula-
tor of T-cell activity.62 Blockade of this signal molecule
has been shown to improve T-cell activity in tumor63
and may prove beneficial in combination with PD-1/PD-
L1 therapies.64 To the best of our knowledge, there are
currently no V-domain Ig suppressor of T-cell activation
−targeted therapies being evaluated for RCC.
LAG-3 is an inhibitory signaling molecule expressed
on T cells and NK cells after binding to major histocom-
patibility complex II and plays a role in protecting nor-
mal cells and tissue from damage by these immune
cells.65 In tumors, LAG-3 frequently is overexpressed
on the tumor-infiltrating lymphocytes that become
exhausted, leading to tumor progression. Blockade of
this pathway has been considered for use in various can-
cers. Currently, there are three clinical trials evaluating
the use of LAG-3 targeting in RCC (NCT03538028,
NCT03849469, and NCT02460224).
CD40 is a cell surface protein that is expressed on the
surface of APCs and B cells and it binds to its ligand
CD154, which resides on T cells. Binding of these two
molecules results in the co-activation of B cells and
T cells with increased cytokine secretion and increased
T-cell activity, respectively.66 It is currently under
investigation in two clinical trials for use in RCC
(NCT03502330 and NCT03538028).
Glucocorticoid-induced tumor necrosis factor−recep-
tor family-related protein, a cell surface protein found on
both T cells and NK cells, is increased markedly after T-
cell activation. Thus, agonism of these proteins has been
considered a therapeutic strategy.64 There are three
active trials in the United States investigating the use of
glucocorticoid-induced tumor necrosis factor−receptor
family-related protein agonists in RCC (NCT02697591,
NCT03277352, and NCT03126110).
CD137 is another cell surface protein expressed by
T cells, NK cells, and APC cells. This protein func-
tions in promoting cell proliferation and activation.67
Ligation of CD137 also promotes antibody-dependent
cell killing by CD8+ T cells and NK cells. Given this
array of effects, it is suitable for complementing with
antibody drugs and potentially vaccine therapy in
RCC because it is able to mediate an antibody-depen-
dent response. Currently, there are two trials underway
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(NCT03809624 and NCT02315066).
CD25 is a cell surface protein that is expressed mainly
on T regulatory cells and depletion of these cells by
blockading CD25 has been considered a potential strat-
egy. Arce Vargas et al68 further developed this concept
by also inactivating inhibitory crystallizable fragment
(Fc) g receptor IIb, which is up-regulated at the tumor
and prevents effective depletion of the T regulatory cells.
They showed that the blockade of the Fc g receptor IIb
and CD25 was effective in increasing the ratio of effec-
tor T cells as well as reducing tumor size in an animal
model.
Antigen presentation by APCs has an important role
in mounting an effective immune response to cancer.
Dendritic cells (DCs) play a vital role in this aspect
through efficient presentation of tumor antigens to CD4+
and CD8+ T cells.69 Based on these activities, the use of
DCs in cancer therapy has been considered.70 AGS-003
is used in DC therapy, in which DCs are electroporated
with tumor RNA and CD40L RNA. The antigens are
presented by the DCs and prime the immune system to
mount a response to the tumor. In a phase II study of
AGS-003 with sunitinib, 62% of RCC patients showed
clinical benefit, with many surviving for 4.5 years or
more.69 Other studies have been performed with similar
strategies and also have shown some clinical promise.71
Along similar lines, cancer vaccines have the same
intent as DC therapies in mounting an effective immune
response to tumors via priming the immune system.
HIF-1a278-287 peptide, a HIF-1a derivative, was shown
to be able to induce tumor-reactive T cells that had
increased efficacy against RCC cells in the peripheral
blood monocytes derived from RCC patients.72 Such
strategies in selecting overexpressed proteins in RCC
can hold promise as a new direction in targeting RCC.
An interesting approach currently is being spearheaded
by the Dana Farber Institute based on the work of Cather-
ine Wu.73 In this approach, sequencing data are collected
from patients and validated. The validated targets then are
put into a prediction model to determine which ones are
able to bind to HLA and synthesized as peptides and
mixed with carboxymethylcellulose, polyinosinic-polycy-
tidylic acid, and poly-L-lysine double-stranded RNA, an
immune adjuvant. The study showed remarkable results
in patients enrolled in the study with 67% of the patients
enrolled having no recurrence 25 months after vaccina-
tion, and 33% of the cases had recurrent disease and sub-
sequent treatment with anti−PD-1 therapy, achieving
complete response.73 This study holds exciting potential
in combination of personalized medicine and in combina-
tion with current immunotherapeutic agents in the effec-
tive treatment of tumors. Sequencing data from patients
can be collected to generate personalized vaccines that
can be used in complement with existing immunothera-
peutics such as anti−PD-1 and anti−PD-L1 therapies toproduce positive outcomes for patients. Based on these
promising studies, a phase I study is currently underway
(NCT02950766) and is expected to be completed by
2022.
Yet another approach is the utilization of engineered
T cells. Chimeric-antigen receptor T cells have been
explored as a possible treatment route. T cells are edited
to include an antigen recognition domain linked to sig-
naling domains that are required for T-cell activity.
These cells then are put into the patient to target the anti-
gen in question.74 This currently is being explored
in RCC (NCT02830724) despite lackluster results in a
prior study.75 Patient-derived T cells also are being eval-
uated for use in the clinic. There is an ongoing trial
(NCT03399448) that is exploring the use of T cells
edited with clustered regularly interspaced short palin-
dromic repeats gene editing to remove the endogenous
T-cell receptor and PD-1 in T cells with the addition of a
New York esophageal squamous cell carcinoma 1, an
antigen present on many cancer cells. This combination
of a tumor-specific antigen complemented with the re-
moval of immune checkpoints would allow for increased
activity against tumor cells in a tumor-suppressive envi-
ronment.Peptide Drugs
Peptides as therapeutic drugs have gained traction in
recent years. Occupying the space between small-mole-
cule drugs and large antibody drugs, peptides offer a
promising combination of good target selectivity, tolera-
bility, and efficacy. Although peptide drugs may possess
some weakness such as chemical and physical instabil-
ity, as well as potential immunogenicity, the field is
expanding and much has been performed to negate these
weaknesses. Alteration of the amino acids and size of
the peptides could reduce the potential for immunogenic-
ity and increase the stability of such drugs.76 In RCC,
there have been a few promising developments in the
past few years.
AMG-386 is a peptide drug with a peptide domain
capable of binding angiopoietin 1 (Ang1) and angiopoie-
tin 2 (Ang2) linked to a Fc region of an antibody. This
drug inhibits the binding of Ang1 and Ang2 to the angio-
poietin 1 receptor. Ang1 and Ang2 binding to angiopoie-
tin 1 receptor are part of the angiogenic process and play
a role in maintaining tumor vasculature.77-79 AMG-386
has shown antitumor activity in treating solid tumors
with one trial observing a partial response in one patient
and four cases of stable disease for more than 16
weeks.80 The peptide drug also had only low-grade tox-
icities and was well tolerated in this study. Currently,
there are two active clinical trials (NCT01664182 and
NCT03239145) investigating the drug as monotherapy
and also as a combination with small-molecule inhibitors
or anti−PD-1 immunotherapy.
Novel therapeutics for kidney cancer 95HBS1 is a protein mimetic of the C-terminal activa-
tion domain of the HIF-1a protein developed by Kushal
et al81 to target the activation of HIF-1a target genes.
The peptide exerts its efficacy through blocking the
interaction of HIF-1a with the transcriptional co-activa-
tors p300 and cAMP response element-binding protein-
binding protein by selectively binding to these transcrip-
tion factors. They show that this targeting was able to
down-regulate various HIF-1a target genes and showed
antitumor activity in a mouse xenograft model. Further-
more, they assessed the toxicity to normal cells and
found minimal toxicities in the range tested from 1 to
100 mmol/L. Although to the best of our knowledge the
peptide has not yet entered into clinical development,
the results shown are promising and the peptide, or simi-
larly designed peptide drugs, may enter into clinical test-
ing in the coming years.
CONCLUSIONS
Over the past decade or so, much development has
occurred in the field of RCC, which has transformed the
field. Although more than a decade ago few tools existed
outside of surgical resection and systemic therapies with
IL2 and IFN, today there is a wide range of targeted ther-
apies and advanced techniques that are being used to
improve patient outcomes and prolong survival. Ranging
from new small-molecule inhibitors to RNA-targeting
strategies, novel immunomodulatory targeting strategies
and the priming/editing of the immune system, there is
much to anticipate in the coming years in the treatment
of RCC. In addition to these novel strategies, a large
number of combination strategies combining these new
novel therapies with other novel therapies or with exist-
ing therapies could provide an even greater benefit in the
treatment of RCC.
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